PLUS1
1.04
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Miragen Therapeutics Inc | MGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 1.04 | 0.00 | 0.00 | 0.00 | 1.04 | 04:38:25 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.9305 | 1.04 | 0.1095 | 10.53% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.04 | USD |
Miragen Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 55.20M | 53.08M | 51.85M | $ 4.46M | $ - | -1.35 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 6.00 | 2.30% |
Miragen Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/22/2020 | 17:35 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/22/2020 | 17:21 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/22/2020 | 17:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/22/2020 | 17:16 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/22/2020 | 17:14 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/22/2020 | 17:10 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/22/2020 | 16:16 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MGEN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.6946 | 1.19 | 0.65 | 1.04 | 3,839,200 | 0.3454 | 49.73% |
| 1 Month | 0.5848 | 1.19 | 0.5451 | 0.9143009 | 1,464,134 | 0.4552 | 77.84% |
| 3 Months | 0.66 | 1.19 | 0.311 | 0.7092433 | 906,627 | 0.38 | 57.58% |
| 6 Months | 0.80 | 2.93 | 0.311 | 1.07 | 1,815,448 | 0.24 | 30.0% |
| 1 Year | 2.36 | 2.93 | 0.311 | 1.09 | 1,025,477 | -1.32 | -55.93% |
| 3 Years | 11.08 | 15.9099 | 0.311 | 2.28 | 461,766 | -10.04 | -90.61% |
| 5 Years | 11.11 | 18.00 | 0.311 | 2.35 | 422,588 | -10.07 | -90.64% |
Miragen Therapeutics Description
| Miragen Therapeutics Inc is a US-based clinical-stage biopharmaceutical company discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical-stage product candidates include Cobomarsen (MRG-106), Remlarsen (MRG-201), MRG-229, and MRG-110. The company mainly focuses on developing such therapeutics which will target blood cancers, pathological fibrosis, and revascularization. |
